Praxis Precision Rg
Practices precision therapeutics for CNS disorders via small‑molecule and antisense platforms. Lead candidates PRAX‑114 (Phase II‑a for major depression) and Ulixacaltamide (Phase III for essential tremor) underscore rapid pipeline progression.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 116
- HQ: Boston
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.